<DOC>
	<DOCNO>NCT00950339</DOCNO>
	<brief_summary>Current guideline recommend addition proton pump inhibitor ( PPI ) patient take double anti-platelet therapy ( Aspirin Clopidogrel ) prevent upper GI bleeding1 . Many post percutaneous coronary intervention ( PCI ) patient treat dual anti-platelet medication well PPI prevent upper GI bleeding . Recently , show PPI interact P450 system liver reduce platelet inhibitory effect Clopidogrel2,3 . Clopidogrel activate CYP2C19 , also metabolize PPI4 . Furthermore , recent article show increased mortality patient take PPI clopidogrel compare patient take clopidogrel without PPI protection5 . The degree reduction platelet inhibitory property clopidogrel might vary among different PPI4 . The use PPI GI protection patient treat dual anti-platelet therapy base randomized trial , rather expert opinion . Since H2 blocker also effective prevent acid secretion know interact P450 system affect clopidogrel , investigator hypothesize group drug interfere positive antiplatelet effect clopidogrel therefore offer good alternative treatment option .</brief_summary>
	<brief_title>Platelet Inhibitory Effect Clopidogrel Patients Treated With Omeprazole , Pantoprazole , Famotidine</brief_title>
	<detailed_description>In study compare 3 different anti-acids regimen effect platelet function</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Histamine H2 Antagonists</mesh_term>
	<criteria>1 . Subject least 18 year old . 2 . Subject willing comply prespecified followup evaluation contact telephone . 3 . Use Clopidogrel ( &gt; =75mg ) Aspirin ( &gt; =75mg ) least 1 month . 1 . Known allergy PPI H2 blockers 2 . Known thrombocytopenia thrombocytopathia 3 . Subject currently enrol another investigational study new drug , biologic device time study screen . NOTE : Subjects participate long term followup phase previously investigational FDAapproved product exclude criterion . 4 . Subject symptomatic heart failure LVEF â‰¤ 25 % 5 . Acute myocardial infarction within past 30 day . 6 . No acute inflammatory event past month ( e.g . infection , autoimmune acute coronary event ) 7 . Concurrent medical condition life expectancy le 12 month . 8 . Known severe renal failure ( serum creatinine level &gt; 2.5 mg/dl ) . 9 . History bleed diathesis coagulopathy inability unwillingness receive blood transfusion . 10 . Evidence active gastrointestinal bleeding history bleed know treated proven resolve . 11 . History hepatitis ( viral , ischemic chemicallyinduced ) ; clinical jaundice , history cirrhosis . 12 . Patient treat anticoagulant medication ( Coumadin , LMWH )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>GI bleeding</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>aspirin</keyword>
	<keyword>prevention</keyword>
	<keyword>angiography</keyword>
</DOC>